Screening and novel therapies for retinopathy of prematurity - A review
- PMID: 31474316
- DOI: 10.1016/j.earlhumdev.2019.104846
Screening and novel therapies for retinopathy of prematurity - A review
Abstract
With current screening for sight threatening retinopathy of prematurity (ROP) <10% of screened infants need treatment. Prediction models based on birth characteristics, postnatal weight gain and other factors have been developed to reduce examinations in low-risk infants. A model based on advanced statistics using data from >7000 infants registered in the Swedish ROP registry is being developed. Based on birth characteristics only, it appears to predict total risk of ROP-treatment as well as models including weight measurements. Treatment risk peaked at 12 weeks of age. Laser therapy is the method of choice for severe ROP. Anti-VEGF therapies are implemented worldwide despite insufficient knowledge of choice of drug, dosage and long term systemic effects. Prevention of ROP may be achieved through oxygen control and provision of the mother's breastmilk. Other interventions such as supplementation with long chain polyunsaturated fatty acids and preservation of fetal haemoglobin are investigated.
Keywords: Prediction; Prevention; Retinopathy of prematurity.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.Clin Perinatol. 2014 Dec;41(4):925-43. doi: 10.1016/j.clp.2014.08.011. Epub 2014 Sep 23. Clin Perinatol. 2014. PMID: 25459781 Free PMC article. Review.
-
ROP: 80 Years after Its Detection - Where Do We Stand and How Long Will We Continue to Laser?Neonatology. 2024;121(5):608-615. doi: 10.1159/000538907. Epub 2024 May 22. Neonatology. 2024. PMID: 38776885 Free PMC article. Review.
-
Validation of the Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) Model.JAMA Ophthalmol. 2017 Aug 1;135(8):871-877. doi: 10.1001/jamaophthalmol.2017.2295. JAMA Ophthalmol. 2017. PMID: 28715553 Free PMC article.
-
Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.Ophthalmic Surg Lasers Imaging Retina. 2019 Apr 1;50(4):228-234. doi: 10.3928/23258160-20190401-05. Ophthalmic Surg Lasers Imaging Retina. 2019. PMID: 30998244 Review.
-
Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.Semin Ophthalmol. 2016;31(1-2):163-8. doi: 10.3109/08820538.2015.1114847. Semin Ophthalmol. 2016. PMID: 26959143 Review.
Cited by
-
Effect of Optimizing Oxygen Saturation Targets on the Incidence of Retinopathy of Prematurity in a Quaternary NICU.Biomed Hub. 2022 Nov 25;7(3):146-155. doi: 10.1159/000527399. eCollection 2022 Sep-Dec. Biomed Hub. 2022. PMID: 36643379 Free PMC article.
-
Extracellular vesicles and preterm infant diseases.Front Pediatr. 2025 Feb 17;13:1550115. doi: 10.3389/fped.2025.1550115. eCollection 2025. Front Pediatr. 2025. PMID: 40034714 Free PMC article. Review.
-
Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial.BMJ Open Ophthalmol. 2022 Apr 8;7(1):e000923. doi: 10.1136/bmjophth-2021-000923. eCollection 2022. BMJ Open Ophthalmol. 2022. PMID: 35495419 Free PMC article. Clinical Trial.
-
Incidence and risk factors of retinopathy of prematurity in an Italian cohort of preterm infants.Ital J Pediatr. 2021 Mar 12;47(1):64. doi: 10.1186/s13052-021-01011-w. Ital J Pediatr. 2021. PMID: 33712037 Free PMC article.
-
Risk factors for the time to development of retinopathy of prematurity in premature infants in Iran: a machine learning approach.BMC Ophthalmol. 2024 Aug 23;24(1):364. doi: 10.1186/s12886-024-03637-w. BMC Ophthalmol. 2024. PMID: 39180010 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources